← Back to Search

N/A

NYX-2925 for Fibromyalgia

Phase 2
Waitlist Available
Research Sponsored by Aptinyx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights

Study Summary

This trial is testing a new drug, NYX-2925, to see if it is effective in treating fibromyalgia.

Eligible Conditions
  • Fibromyalgia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the Mean Numerical Rating Scale (NRS) Score
Secondary outcome measures
Daily Sleep Interference (DSIS) Score
Fibromyalgia Impact Questionnaire-Revised (FIQR) Score
Number of Subjects "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGI-C) at Week 12
+6 more

Side effects data

From 2022 Phase 2 trial • 310 Patients • NCT04147858
6%
Urinary tract infection
6%
COVID-19
4%
Nausea
4%
Headache
2%
Diarrhea
1%
Fatigue
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
NYX-2925 100 mg
NYX-2925 50 mg

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: NYX-2925 50 mgExperimental Treatment1 Intervention
NYX-2925 50 mg administered orally.
Group II: NYX-2925 100 mgExperimental Treatment1 Intervention
NYX-2925 100 mg administered orally.
Group III: PlaceboPlacebo Group1 Intervention
Placebo administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NYX-2925
2016
Completed Phase 2
~720

Find a Location

Who is running the clinical trial?

AptinyxLead Sponsor
8 Previous Clinical Trials
1,024 Total Patients Enrolled
1 Trials studying Fibromyalgia
22 Patients Enrolled for Fibromyalgia
Worldwide Clinical TrialsOTHER
61 Previous Clinical Trials
14,077 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
2019. "Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04147858.
~57 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top